Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13885541 | 0.88 | GAA (0.74) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL13647658 | 0.87 | GAA (0.60) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL7295331 | 0.86 | RAB9A (0.67) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL3919080 | 0.85 | GAA (0.59) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL12651964 | 0.85 | NPC1 (0.60) | GAAHTTMAPTRAB9ANPC1 | |
| SCHEMBL20511115 | 0.83 | MAPT (0.65) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9525322 | 0.83 | NPC1 (0.59) | GAAMAPTRAB9ANPC1PTGS1 | |
| SCHEMBL11769542 | 0.82 | POLB (0.77) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30288146 | 0.82 | POLB (0.77) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL96026 | 0.81 | MAPT (0.63) | HTTMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476430-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| WO-2010011837-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | GAA 4154/4885HTT 4403/4885MAPT 4866/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | GAA 4119/4885HTT 4284/4885MAPT 4863/4885 |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | GAA 3640/4885HTT 3963/4885MAPT 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.